RXST enters the week following its Q1 earnings release with a notable shift in short positioning — shorts that built aggressively through late April are now unwinding, even as the stock trades at just $7.26.
Short interest has been the dominant story for RXST in recent weeks. It peaked at roughly 16.6% of the free float in early April, then briefly compressed before rebuilding to around 15.7% by late April. The move since has been meaningfully lower — SI hit 14.4% by May 5, down about 7% in a single day and off more than 5% over the past month. The official FINRA fortnightly figure is aligned, putting exchange-reported short interest at 5.57 million shares as of mid-April settlement. At 13 full days to cover on the official count, any fast covering would need real trading volume to work through.
The borrow market adds a layer of nuance. Cost to borrow has been erratic — bouncing between 0.41% and 2.03% over the past six weeks — suggesting a thin and lumpy lending pool rather than a structural squeeze. The current reading at 1.48% is elevated versus April levels but well off its intraday spikes. Availability has been wide enough not to create a hard constraint on new shorts, but the CTB volatility signals that the borrowing pool is not deep. Short availability is running loosely, consistent with a stock that is heavily shorted but not yet in acute borrow stress.
Options positioning has shifted since mid-April. The put/call ratio ran above 1.0 through most of that period — reaching 1.08 at its peak — before dropping sharply to 0.82 this week. That retreat from defensive positioning is mildly constructive. The current PCR is slightly below its 20-day mean of 0.87, a mild z-score of -0.30. Nothing extreme either way. The 52-week PCR range is extraordinarily wide — from 0.13 to 3.15 — which reflects how episodically sentiment has swung on this stock. The current reading sits comfortably in the middle of that range, offering no strong directional signal.
The Street is divided and the bulls are in the minority. Needham stands as the lone buy-rated firm among recent participants, holding a $13 target — the most constructive voice on the name by a considerable margin. Stifel, UBS, and Piper Sandler cluster around Hold and Neutral ratings, with targets between $9 and $10. The mean analyst target of $9.79 implies roughly 35% upside to the current price of $7.26, which on its face sounds compelling. However, the most recent changes — Stifel cutting to $9 in March and Piper Sandler trimming to $10 in February — reflect a Street that has been lowering the bar rather than raising it since the Q3 2025 reports. The bear case is concrete: 2026 guidance disappointed, LDD placements are tracking below expectations, and the revenue mix could be pressured by higher-priced inventory dynamics in the second half. The bull case hinges on installed base growth and rising utilization of the Light Adjustable Lens (LAL) platform, which has a genuinely differentiated product position in cataract surgery.
The EPS momentum story is a rare bright spot. The stock ranks in the 87th percentile on 30-day EPS momentum and the 84th on 90-day — suggesting that while reported results have been below original expectations, estimate revisions have recently been moving in a positive direction. The stock also ranks in the 75th percentile on EPS surprise, consistent with a pattern of beating lowered bars. YTD the stock is down 30%, but the one-month move of 9% suggests a tentative floor is forming after the sell-off. Peer DCTH gained 9.3% over the past week while LUNG added 3.3%, both slightly outpacing RXST's 1.3% weekly recovery — a modest underperformance for a stock that has lagged more sharply on a longer horizon.
The next earnings event is flagged for June 16. Between now and then, the question for positioning is whether the short-covering that started this week has further to run, or whether fresh supply re-enters as the stock approaches the analyst cluster of price targets around $9–$10.
See the live data behind this article on ORTEX.
Open RXST on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
